0000000000741837

AUTHOR

Jessica Galli

showing 2 related works from this author

Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one

2017

lcsh:Diseases of the musculoskeletal systemlcsh:RJ1-570lcsh:Pediatricslcsh:RC925-935Meeting Abstracts
researchProduct

Case Report: The JAK-Inhibitor Ruxolitinib Use in Aicardi-Goutieres Syndrome Due to ADAR1 Mutation

2021

Type I Interferonopathies comprise inherited inflammatory diseases associated with perturbation of the type I IFN response. Use of Janus kinase (JAK) inhibitors has been recently reported as possible tools for treating some of those rare diseases. We describe herein the clinical picture and treatment response to the JAK-inhibitor ruxolitinib in a 5-year-old girl affected by Aicardi-Goutières Syndrome type 6 (AGS6) due to ADAR1 mutation. The girl's interferon score (IS) was compared with that of her older brother, suffering from the same disorder, who was not treated. We observed a limited, but distinct neurological improvement (Gross Motor Function and Griffiths Mental Development Scales). …

Mental developmentRuxolitinibMutationTreatment responseAicardi-Goutières syndrome; JAK-inhibitor; interferonopathies; ruxolitinib; type I interferonbusiness.industryOlder brotherruxolitinibJAK-inhibitorCase ReportAicardi-Goutières syndromemedicine.diseasemedicine.disease_causePediatricsRJ1-570interferonopathiesInterferonImmunologyPediatrics Perinatology and Child HealthmedicineAicardi–Goutières syndrometype I interferonJanus kinasebusinessmedicine.drugFrontiers in Pediatrics
researchProduct